WGVRP
MCID: WGN007
MIFTS: 38

Wagner Vitreoretinopathy (WGVRP)

Categories: Eye diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Wagner Vitreoretinopathy

MalaCards integrated aliases for Wagner Vitreoretinopathy:

Name: Wagner Vitreoretinopathy 57 74
Hyaloideoretinal Degeneration of Wagner 57 74 72
Wagner Syndrome 1 57 74 13
Wagner Vitreoretinal Degeneration 57 74
Erosive Vitreoretinopathy 57 74
Wgvrp 57 74
Ervr 57 74
Wgn1 57 74
Dominant Hyaloideoretinal Dystrophy of Wagner 59
Vitreoretinal Degeneration, Wagner Type 59
Erosive Vitreoretinopathy; Ervr 57
Vcan-Related Vitreoretinopathy 59
Vitreoretinopathy, Wagner 40
Wagner Syndrome 1; Wgn1 57
Wagner Syndrome 59
Wagner Disease 59

Characteristics:

Orphanet epidemiological data:

59
wagner disease
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: Childhood; Age of death: normal life expectancy;

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
progressive clinical course with onset in childhood


HPO:

32
wagner vitreoretinopathy:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare eye diseases


External Ids:

OMIM 57 143200
MeSH 44 D012162
MESH via Orphanet 45 C536075
ICD10 via Orphanet 34 H35.5
UMLS via Orphanet 73 C0339540 C1840452
Orphanet 59 ORPHA898
UMLS 72 C1840452

Summaries for Wagner Vitreoretinopathy

OMIM : 57 Wagner vitreoretinopathy is a rare vitreoretinal degeneration inherited as an autosomal dominant trait, first described in a large Swiss pedigree (Wagner, 1938) and subsequently identified in other families. Penetrance in Wagner syndrome is complete, and the disease manifests in childhood or adolescence with a progressive course. Affected individuals usually present with an 'empty' vitreous cavity with fibrillary condensation or avascular strands and veils. Additional features, which are variable and age-dependent, include chorioretinal atrophy with loss of the retinal pigment epithelium (RPE), lattice degeneration of the retina, complicated cataracts, mild myopia, and peripheral traction retinal detachment. Rod and cone electroretinography shows reduced b-wave amplitude and correlates with severe chorioretinal pathology. It is believed that liquefaction of vitreous initiates a degenerative cascade that results in the complex eye phenotype of Wagner syndrome (summary by Kloeckener-Gruissem et al., 2006). Patients with additional ocular features such as progressive nyctalopia (night blindness), visual field constriction, and chorioretinal atrophy, with loss of RPE and choriocapillaries on fluorescein angiography and rod-cone abnormalities on electroretinography, were initially believed to have a distinct clinical entity, which was designated 'erosive vitreoretinopathy' (ERVR). Extraocular abnormalities are not present in patients diagnosed with Wagner or erosive vitreoretinopathy (summary by Mukhopadhyay et al., 2006). (143200)

MalaCards based summary : Wagner Vitreoretinopathy, also known as hyaloideoretinal degeneration of wagner, is related to stickler syndrome, type i, nonsyndromic ocular and wagner syndrome. An important gene associated with Wagner Vitreoretinopathy is VCAN (Versican). The drugs Peginterferon alfa-2b and Methylcobalamin have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and bone, and related phenotypes are exudative vitreoretinopathy and cataract

UniProtKB/Swiss-Prot : 74 Wagner vitreoretinopathy: A rare vitreoretinopathy characterized by an optically empty vitreous cavity with fibrillary condensations and a preretinal avascular membrane. Other optical features include progressive chorioretinal atrophy, perivascular sheating, subcapsular cataract and myopia.

Related Diseases for Wagner Vitreoretinopathy

Diseases related to Wagner Vitreoretinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 30)
# Related Disease Score Top Affiliating Genes
1 stickler syndrome, type i, nonsyndromic ocular 11.5
2 wagner syndrome 11.5
3 cataract 10.4
4 uveitis 10.3
5 night blindness 10.3
6 refractive error 10.3
7 vitreoretinopathy 10.3
8 retinal detachment 10.3
9 choroideremia 10.2
10 yemenite deaf-blind hypopigmentation syndrome 10.2
11 neovascular glaucoma 10.2
12 vitreous syneresis 10.2
13 stickler syndrome 10.0
14 myopia 10.0
15 scotoma 10.0
16 vcan-related vitreoretinopathy 10.0
17 goldmann-favre syndrome 10.0
18 vitreoretinal degeneration 10.0
19 stickler syndrome, type i 9.9
20 retinitis pigmentosa 9.9
21 norrie disease 9.9
22 branchiootic syndrome 1 9.9
23 intraocular pressure quantitative trait locus 9.9
24 cone dystrophy 9.9
25 optic nerve disease 9.9
26 arthropathy 9.9
27 macular retinal edema 9.9
28 neuropathy 9.9
29 anterior uveitis 9.9
30 collagenopathy type 2 alpha 1 9.9

Graphical network of the top 20 diseases related to Wagner Vitreoretinopathy:



Diseases related to Wagner Vitreoretinopathy

Symptoms & Phenotypes for Wagner Vitreoretinopathy

Human phenotypes related to Wagner Vitreoretinopathy:

32 (show all 12)
# Description HPO Frequency HPO Source Accession
1 exudative vitreoretinopathy 32 occasional (7.5%) HP:0030490
2 cataract 32 HP:0000518
3 optic atrophy 32 HP:0000648
4 myopia 32 HP:0000545
5 visual field defect 32 HP:0001123
6 glaucoma 32 HP:0000501
7 visual loss 32 HP:0000572
8 chorioretinal atrophy 32 HP:0000533
9 vitreoretinopathy 32 HP:0007773
10 retinal pigment epithelial atrophy 32 HP:0007722
11 peripheral tractional retinal detachment 32 HP:0007643
12 optically empty vitreous 32 HP:0030663

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Eyes:
cataract
glaucoma
loss of retinal pigment epithelium
vitreoretinal degeneration
chorioretinal atrophy
more

Clinical features from OMIM:

143200

Drugs & Therapeutics for Wagner Vitreoretinopathy

Drugs for Wagner Vitreoretinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
2
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
3
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
4
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
5
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
6
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
7
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
8
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
9
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
10
Cobalamin Experimental Phase 4 13408-78-1 6857388
11 interferons Phase 4
12 Interferon-alpha Phase 4
13 Interferon alpha-2 Phase 4
14 Immunologic Factors Phase 4
15 Trace Elements Phase 4
16 Micronutrients Phase 4
17 Hormones Phase 4
18 Vitamin D2 Phase 4
19 Vitamins Phase 4
20 Hematinics Phase 4
21 Ergocalciferols Phase 4
22 Vitamin B 12 Phase 4
23 Vitamin B9 Phase 4
24 Nutrients Phase 4
25 Folate Phase 4
26 Vitamin B Complex Phase 4
27 Vitamin B12 Phase 4
28 Calciferol Phase 4
29 Calcium, Dietary Phase 4
30 Bone Density Conservation Agents Phase 4
31
Sofosbuvir Approved Phase 2 1190307-88-0 45375808

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
2 Randomized Clinical Trial to Assess the Effectiveness of Vitamin D and Vitamin B12 Supplementation in Combination With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C. Terminated NCT02120274 Phase 4 Vitamin D;Vitamin B 12
3 A Randomized Trial of Telaprevir, Peginterferon, and Ribavirin Versus Peginterferon and Ribavirin for Treatment of Genotype 1 Hepatitis C Virus With Host Interleukin 28B CC Polymorphism Withdrawn NCT01415141 Phase 4 Peginterferon alfa-2a;Ribavirin;telaprevir
4 A Multi-center, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Pegylated Interferon and Ribavirin in Treatment-Naïve Patients With Chronic HCV Infection Genotype 1, and an Open Label Assessment of PSI-7977 in Patients With HCV Genotypes 2 or 3 Completed NCT01188772 Phase 2 Sofosbuvir;Placebo to match sofosbuvir;PEG;RBV
5 A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2336805 With Pegylated Interferon and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 or 4 Hepatitis C Infection Completed NCT01648140 Phase 2 GSK2336805 40 mg;GSK2336805 60 mg;Pegylated interferon alpha-2a;Ribavirin;Telaprevir

Search NIH Clinical Center for Wagner Vitreoretinopathy

Genetic Tests for Wagner Vitreoretinopathy

Anatomical Context for Wagner Vitreoretinopathy

MalaCards organs/tissues related to Wagner Vitreoretinopathy:

41
Eye, Retina, Bone

Publications for Wagner Vitreoretinopathy

Articles related to Wagner Vitreoretinopathy:

(show all 23)
# Title Authors PMID Year
1
Identification of a novel splice site mutation of the CSPG2 gene in a Japanese family with Wagner syndrome. 38 8 71
16043844 2005
2
Novel VCAN mutations and evidence for unbalanced alternative splicing in the pathogenesis of Wagner syndrome. 8 71
22739342 2013
3
A new VCAN/versican splice acceptor site mutation in a French Wagner family associated with vascular and inflammatory ocular features. 8 71
21738396 2011
4
Erosive vitreoretinopathy and wagner disease are caused by intronic mutations in CSPG2/Versican that result in an imbalance of splice variants. 8 71
16877430 2006
5
Identification of the genetic defect in the original Wagner syndrome family. 8 71
16636652 2006
6
Wagner vitreoretinal degeneration with genetic linkage refinement on chromosome 5q13-q14. 8 71
10333105 1999
7
Exclusion of COL2A1 as a candidate gene in a family with Wagner-Stickler syndrome. 8 71
2319589 1990
8
VCAN-Related Vitreoretinopathy 71
20301747 2009
9
High efficiency of mutation detection in type 1 stickler syndrome using a two-stage approach: vitreoretinal assessment coupled with exon sequencing for screening COL2A1. 8
16752401 2006
10
A novel hereditary developmental vitreoretinopathy with multiple ocular abnormalities localizing to a 5-cM region of chromosome 5q13-q14. 8
10571340 1999
11
Wagner vitreoretinal degeneration. Follow-up of the original pedigree. 8
9098284 1995
12
Genetic linkage of Wagner disease and erosive vitreoretinopathy to chromosome 5q13-14. 8
7748141 1995
13
Erosive vitreoretinopathy. A new clinical entity. 8
8152765 1994
14
Mutation in type II procollagen (COL2A1) that substitutes aspartate for glycine alpha 1-67 and that causes cataracts and retinal detachment: evidence for molecular heterogeneity in the Wagner syndrome and the Stickler syndrome (arthro-ophthalmopathy) 8
8317498 1993
15
The Wagner-Stickler syndrome: a study of 22 families. 8
7264793 1981
16
Hereditary progressive arthro-ophthalmopathy of Stickler. 8
507166 1979
17
Wagner's hereditary vitreoretinal degeneration and retinal detachment. 8
4691317 1973
18
Degeneratio hyaloideo-retinalis herditaria. 8
14041873 1962
19
[On the clinical manifestation and pathology of degeneratio hyaloideoretinalis hereditaria (Wagner)]. 8
13802004 1960
20
Clinical features of the congenital vitreoretinopathies. 38
18309337 2008
21
Analysis of the rdd locus in chicken: a model for human retinitis pigmentosa. 38
12724645 2003
22
Stickler syndrome and vitreoretinal degeneration: correlation between locus mutation and vitreous phenotype. Apropos of a case. 38
11450497 2001
23
Refined genetic and physical localization of the Wagner disease (WGN1) locus and the genes CRTL1 and CSPG2 to a 2- to 2.5-cM region of chromosome 5q14.3. 38
10198161 1999

Variations for Wagner Vitreoretinopathy

ClinVar genetic disease variations for Wagner Vitreoretinopathy:

6 (show top 50) (show all 164)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 VCAN NM_004385.5(VCAN): c.4004-2A> G single nucleotide variant Pathogenic rs80356555 5:82832824-82832824 5:83537005-83537005
2 VCAN NM_004385.5(VCAN): c.4004-1G> A single nucleotide variant Pathogenic rs80356554 5:82832825-82832825 5:83537006-83537006
3 VCAN NM_004385.5(VCAN): c.4004-5T> A single nucleotide variant Pathogenic rs80356556 5:82832821-82832821 5:83537002-83537002
4 VCAN NM_004385.5(VCAN): c.4004-5T> C single nucleotide variant Pathogenic rs80356556 5:82832821-82832821 5:83537002-83537002
5 VCAN NM_004385.5(VCAN): c.9265+1G> A single nucleotide variant Pathogenic rs80356553 5:82838088-82838088 5:83542269-83542269
6 VCAN NM_004385.5(VCAN): c.9265+2T> A single nucleotide variant Pathogenic rs397515437 5:82838089-82838089 5:83542270-83542270
7 VCAN NM_004385.5(VCAN): c.4004-1G> C single nucleotide variant Pathogenic rs80356554 5:82832825-82832825 5:83537006-83537006
8 VCAN NM_004385.5(VCAN): c.4004-2A> T single nucleotide variant Pathogenic rs80356555 5:82832824-82832824 5:83537005-83537005
9 VCAN NM_004385.5(VCAN): c.4004-6T> A single nucleotide variant Pathogenic rs864309744 5:82832820-82832820 5:83537001-83537001
10 VCAN NM_004385.5(VCAN): c.4004-1G> T single nucleotide variant Pathogenic rs80356554 5:82832825-82832825 5:83537006-83537006
11 VCAN NM_004385.5(VCAN): c.9265+1G> T single nucleotide variant Pathogenic rs80356553 5:82838088-82838088 5:83542269-83542269
12 VCAN NM_004385.5(VCAN): c.6902T> G (p.Phe2301Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs160278 5:82835724-82835724 5:83539905-83539905
13 VCAN NM_004385.5(VCAN): c.5859G> T (p.Thr1953=) single nucleotide variant Conflicting interpretations of pathogenicity rs80028865 5:82834681-82834681 5:83538862-83538862
14 VCAN NM_004385.5(VCAN): c.6767T> C (p.Leu2256Pro) single nucleotide variant Conflicting interpretations of pathogenicity rs146630369 5:82835589-82835589 5:83539770-83539770
15 VCAN NM_004385.5(VCAN): c.-135G> A single nucleotide variant Uncertain significance rs886060814 5:82767714-82767714 5:83471895-83471895
16 VCAN NM_004385.5(VCAN): c.930G> A (p.Val310=) single nucleotide variant Uncertain significance rs886060818 5:82808103-82808103 5:83512284-83512284
17 VCAN NM_004385.5(VCAN): c.2937C> T (p.Pro979=) single nucleotide variant Uncertain significance rs886060819 5:82817062-82817062 5:83521243-83521243
18 VCAN NM_004385.5(VCAN): c.3067A> G (p.Thr1023Ala) single nucleotide variant Uncertain significance rs886060820 5:82817192-82817192 5:83521373-83521373
19 VCAN NM_004385.5(VCAN): c.3956A> G (p.His1319Arg) single nucleotide variant Uncertain significance rs886060822 5:82818081-82818081 5:83522262-83522262
20 VCAN NM_004385.5(VCAN): c.4236T> C (p.Asn1412=) single nucleotide variant Uncertain significance rs752922531 5:82833058-82833058 5:83537239-83537239
21 VCAN NM_004385.5(VCAN): c.4248C> T (p.Leu1416=) single nucleotide variant Uncertain significance rs758617685 5:82833070-82833070 5:83537251-83537251
22 VCAN NM_004385.5(VCAN): c.-75A> G single nucleotide variant Uncertain significance rs886060816 5:82767774-82767774 5:83471955-83471955
23 VCAN NM_004385.5(VCAN): c.5482C> T (p.Pro1828Ser) single nucleotide variant Uncertain significance rs886060823 5:82834304-82834304 5:83538485-83538485
24 VCAN NM_004385.5(VCAN): c.5801T> G (p.Phe1934Cys) single nucleotide variant Uncertain significance rs886060824 5:82834623-82834623 5:83538804-83538804
25 VCAN NM_004385.5(VCAN): c.7035G> A (p.Thr2345=) single nucleotide variant Uncertain significance rs200757689 5:82835857-82835857 5:83540038-83540038
26 VCAN NM_004385.5(VCAN): c.8058A> C (p.Leu2686Phe) single nucleotide variant Uncertain significance rs780717994 5:82836880-82836880 5:83541061-83541061
27 VCAN NM_004385.5(VCAN): c.8064C> T (p.Pro2688=) single nucleotide variant Uncertain significance rs886060827 5:82836886-82836886 5:83541067-83541067
28 VCAN NM_004385.5(VCAN): c.*905_*912del deletion Uncertain significance rs886060834 5:82877158-82877165 5:83581339-83581346
29 VCAN NM_004385.5(VCAN): c.*1031T> C single nucleotide variant Uncertain significance rs548595991 5:82877284-82877284 5:83581465-83581465
30 VCAN NM_004385.5(VCAN): c.*1091C> T single nucleotide variant Uncertain significance rs886060836 5:82877344-82877344 5:83581525-83581525
31 VCAN NM_004385.5(VCAN): c.-259C> T single nucleotide variant Uncertain significance rs886060813 5:82767590-82767590 5:83471771-83471771
32 VCAN NM_004385.5(VCAN): c.109T> G (p.Ser37Ala) single nucleotide variant Uncertain significance rs142740596 5:82785955-82785955 5:83490136-83490136
33 VCAN NM_004385.5(VCAN): c.3103T> G (p.Phe1035Val) single nucleotide variant Uncertain significance rs886060821 5:82817228-82817228 5:83521409-83521409
34 VCAN NM_004385.5(VCAN): c.5427C> T (p.His1809=) single nucleotide variant Uncertain significance rs779803420 5:82834249-82834249 5:83538430-83538430
35 VCAN NM_004385.5(VCAN): c.6201A> G (p.Glu2067=) single nucleotide variant Uncertain significance rs780184359 5:82835023-82835023 5:83539204-83539204
36 VCAN NM_004385.5(VCAN): c.7895C> T (p.Thr2632Ile) single nucleotide variant Uncertain significance rs767660495 5:82836717-82836717 5:83540898-83540898
37 VCAN NM_004385.5(VCAN): c.8063C> T (p.Pro2688Leu) single nucleotide variant Uncertain significance rs755806449 5:82836885-82836885 5:83541066-83541066
38 VCAN NM_004385.5(VCAN): c.8454G> A (p.Ala2818=) single nucleotide variant Uncertain significance rs773474075 5:82837276-82837276 5:83541457-83541457
39 VCAN NM_001164097.1(VCAN): c.-334C> T single nucleotide variant Uncertain significance rs886060812 5:82767515-82767515 5:83471696-83471696
40 VCAN NM_004385.5(VCAN): c.-89T> C single nucleotide variant Uncertain significance rs886060815 5:82767760-82767760 5:83471941-83471941
41 VCAN NM_004385.5(VCAN): c.297G> C (p.Gly99=) single nucleotide variant Uncertain significance rs886060817 5:82786143-82786143 5:83490324-83490324
42 VCAN NM_004385.5(VCAN): c.*883_*885del deletion Uncertain significance rs886060832 5:82877136-82877138 5:83581317-83581319
43 VCAN NM_004385.5(VCAN): c.*898_*905delinsG indel Uncertain significance rs886060833 5:82877151-82877158 5:83581332-83581339
44 VCAN NM_004385.5(VCAN): c.5836C> T (p.His1946Tyr) single nucleotide variant Uncertain significance rs886060825 5:82834658-82834658 5:83538839-83538839
45 VCAN NM_004385.5(VCAN): c.*1671C> T single nucleotide variant Uncertain significance rs776524825 5:82877924-82877924 5:83582105-83582105
46 VCAN NM_004385.5(VCAN): c.3204C> T (p.Gly1068=) single nucleotide variant Uncertain significance rs142805131 5:82817329-82817329 5:83521510-83521510
47 VCAN NM_004385.5(VCAN): c.3264A> G (p.Pro1088=) single nucleotide variant Uncertain significance rs767745674 5:82817389-82817389 5:83521570-83521570
48 VCAN NM_004385.5(VCAN): c.*813_*816dup duplication Uncertain significance rs140261411 5:82877066-82877069 5:83581247-83581250
49 VCAN NM_004385.5(VCAN): c.*160A> G single nucleotide variant Uncertain significance rs886060828 5:82876413-82876413 5:83580594-83580594
50 VCAN NM_004385.5(VCAN): c.9481C> G (p.Leu3161Val) single nucleotide variant Uncertain significance rs765359111 5:82843891-82843891 5:83548072-83548072

Expression for Wagner Vitreoretinopathy

Search GEO for disease gene expression data for Wagner Vitreoretinopathy.

Pathways for Wagner Vitreoretinopathy

GO Terms for Wagner Vitreoretinopathy

Sources for Wagner Vitreoretinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....